Nivolumab to control molecular response in Chronic Myeloid Leukemia

The PD-1/PD-L1 (programmed cell death) pathway is an immune checkpoint, which protects normal tissues but can also prevent anti-tumor immune response. The FDA approvals of checkpoint inhibitors constitutes a major advance in the immunotherapy of cancer [1]. Chronic myeloid leukemia (CML) is an example of successful use of tyrosine kinase inhibitors (TKIs). Blockade of oncogenic BCR-ABL1 kinase activity translated into an impressive control of the disease. CML is also known to be responsive to immunotherapy and long-term eradication of CML has been achieved by allogeneic hematopoietic stem cell transplantation [2].

Source: Leukemia Research - July 15, 2018 Category: Hematology Authors: Philippe Rousselot, Perrine Renard, Ariane de Buyer, Adeline Finet, Marc Spentchian, Philippe Saiag Tags: Letter to the Editor Source Type: research